Aerie Pharma (AERI) Reports Q2 Loss of $1.40/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Aerie Pharma (AERI) PT Raised to $105 at Cowen
August 9, 2018 9:39 AM EDTCowen raised its price target on Aerie Pharma (NASDAQ: AERI) to $105.00 (from $100.00) while maintaining an Outperform rating.
Analyst Ken Cacciatore notes the company continues to methodically secure managed care access for Rhopressa and broaden the clinician user base. This is... More
